Pfizer Inc. (NYSE:PFE) is included among the 10 Innovative Dividend Stocks to Buy Right Now.

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The agreement extends U.S. exclusivity for Vyndamax to June 1, 2031. The firm said that, based on recent conversations, this outcome sits at the lower end of investor expectations of 2031/2032. The analyst added that the settlement suggests the polymorph patent, which expires in 2035, is “likely not very strong.”

Pfizer developed a form of santonin used to treat intestinal worms. The treatment gained popularity due to its effectiveness. One of its founders, Erhart, used his background in candy-making to add an almond-toffee flavor, which made the medicine easier to take. Around the same time, the company began producing citric acid, an ingredient used in beverages like Coca-Cola. This product became a core part of the business and supported growth over the following decades.

Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company. It focuses on the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best High-Yield Dividend Growth Stocks to Buy Right Now and 10 Large-Cap Stocks That Are On Fire Right Now

Disclosure: None. Follow Insider Monkey on Google News.